The American Society for Colposcopy and Cervical Pathology (ASCCP) reaffirms its strong support for the human papillomavirus (HPV) vaccine as a proven and essential tool in the prevention of HPV-related cancers and precancers. 

As the leading medical society dedicated to the prevention and management of HPV-related disease, ASCCP continues to advocate for evidence-based recommendations that reflect the best available science. The HPV vaccine remains one of the most powerful tools we have to prevent cervical and other anogenital cancers, as well as the precancerous lesions that can require invasive treatment and affect reproductive health. 

ASCCP fully supports the current Advisory Committee on Immunization Practices (ACIP) guidelines, which recommend routine HPV vaccination for adolescents and young adults based on extensive scientific evidence demonstrating the vaccine’s safety, durability, and effectiveness in preventing both cancers and precancers. 

For adults aged 27–45 years, ASCCP supports ACIP’s recommendation that HPV vaccination may be offered through shared clinical decision making. In this age group, clinicians and patients should briefly discuss the individual’s risk for new HPV infection, the potential but smaller benefit of vaccination, and personal preferences to determine whether vaccination is appropriate. 

ASCCP also reaffirms its recommendation that adjuvant HPV vaccination be offered at the time of treatment for histologic HSIL (CIN2/3), adenocarcinoma in situ (AIS), and other HPV-related precancers, for previously unvaccinated individuals. Evidence—including recent reviews and meta-analyses—supports that adjuvant HPV vaccination reduces the risk of recurrence after treatment, helping prevent future disease and the need for additional procedures. 

We remain steadfast in our commitment to advancing HPV vaccination, education, and research, and to promoting its use in accordance with current, evidence-based ACIP guidelines. ASCCP will continue to champion the science behind HPV vaccination and advocate for its use as an essential cornerstone of cancer prevention worldwide. 

Approved by the Executive Board: December 12, 2025